Main Menu

Our Work

In re Teva Securities Litigation 

In In re Teva Securities Litigation, Eric Gaier was retained on behalf of Teva Pharmaceuticals to analyze allegations by class plaintiffs that certain Teva executives misrepresented the source of Teva’s profit success and the competitive nature of markets for generic drugs. Dr. Gaier testified on antitrust issues associated with alleged collusion in generic drug markets and the sources of Teva’s profits.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.